What is ALS Phase 3 Study VITALITY-ALS?

Category: Others

false

The ALS Phase 3 Study VITALITY-ALS clinical trial is examining the safety, tolerability and efficacy of tirasemtiv in patients with ALS. The clinical trial number is NCT02496767.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 1
Moderate 5
Mild 11
None 15

Commonly reported side effects and conditions associated with ALS Phase 3 Study VITALITY-ALS

Side effect Patients
Dizziness 3
Fatigue 3
Constipation 1
Drowsiness 1
Irritability 1
Lightheadedness 1

Show all 8 reported side effects

Dosages

Based on patients currently using ALS Phase 3 Study VITALITY-ALS

Dosage Patients
2 other twice daily 1
100 mg twice daily 1
250 mg daily 1

Why patients stopped taking ALS Phase 3 Study VITALITY-ALS

Multiple reasons could be selected

Reason Patients
Side effects too severe 3
Doctor's advice 2
Course of treatment ended 1
See all 5 patients who've stopped using ALS Phase 3 Study VITALITY-ALS

Duration

Currently using ALS Phase 3 Study VITALITY-ALS

Duration Patients
2 - 5 years 4

Stopped using ALS Phase 3 Study VITALITY-ALS

Duration Patients
Less than 1 month 1
1 - 6 months 1
6 months - 1 year 2
1 - 2 years 1
Adherence
Adherence Evaluations
Always 32
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 3
A little hard to take 16
Not at all hard to take 13
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 22
Not specified 10
Last updated:
There are no evaluations for ALS Phase 3 Study VITALITY-ALS.